Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Semaglutide works by slowing stomach emptying and signaling fullness to your brainmechanisms that frequently trigger mild to moderate nausea during the first few weeks of treatment
building muscle at the gym is harder than it used to be
PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways, providing providers context on predispositions within peptide-signaling networks
